Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Faron Pharmaceuticals

Analyytikko

Viimeisin video

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
28.7.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron Pharmaceuticals to Report Half-Year Financial Results on Thursday, August 26, 2021

 

Company announcement, July 28, 2021 at 7:00 am BST / 9:00 am EEST

Tiedotteet
22.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Updated corporate presentation

Company announcement, 22 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, has today published an updated corporate presentation on its website.

The presentation contains previously published Company information, views of Management and data from Faron's development programmes.

Tiedotteet
14.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Bexmarilimab granted key US patent

Company announcement, 14 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 11,046,761, with claims protecting the composition of matter of bexmarilimab. The patent will be issued on 29 June, 2021.

Tiedotteet
3.6.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

First-in-human bexmarilimab results published in Clinical Cancer Research

- Results reveal the role of Clever-1 receptor in supressing adaptive immunity

- Bexmarilimab's macrophage-targeting approach activates T-cells and drives anti-tumour immune responses in cold tumours that are not otherwise responsive to immunotherapy

Company announcement, 3 June 2021 at 9.00 AM (EET)
 

inderesTV
2.6.
2021

Faron Pharmaceuticals - Toimitusjohtaja Markku Jalkanen (kohdasta 08:22 alkaen)

Tiedotteet
17.5.
2021

 Faron Pharmaceuticals Oy

("Faron" or the "Company")

Tiedotteet
14.5.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron secures U.S. rights to patent related to Traumakine 

Company announcement, 14 May 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has signed a sub-license agreement for the rights to U.S. patent US9,376,478, which currently extends to 2033.

Tiedotteet
10.5.
2021

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

Tiedotteet
29.4.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Grant of options

Company announcement, 29 April 2021 at 14.45 (EEST)

Tiedotteet
23.4.
2021

Faron Pharmaceuticals Oy

 

("Faron" or the "Company")

Board Change

Company announcement, 23 April 2021 at 15:45 EET

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Anne Whitaker as a Non-Executive Director of the Company following the passing of all resolutions put to shareholders of the Company at the AGM held earlier today. 

Faron Pharmaceuticals